Helix Acquisition II Increases IPO Size

Helix Acquisition II, a blank-check company, has announced an increase in the size of its anticipated initial public offering. According to a recent regulatory filing, the company now plans to sell 15 million shares at an expected price of $10 each, with expected gross proceeds of $150 million. This is a significant increase from the previously planned $100 million IPO.

Potential Merger in the Healthcare Industry

Helix Acquisition II aims to merge with a company operating in the healthcare or healthcare-related industries. This move aligns with the company's overall strategy and investment focus.

Affiliation with Cormorant

Cormorant, a well-known life-sciences investment firm, is the sponsor of Helix Acquisition II. This affiliation provides valuable expertise and resources to support the company's goals.

Successful Merger History

Helix Acquisition Corp., a previous special-purpose acquisition company (SPAC) associated with Cormorant, successfully merged with MoonLake Immunotherapeutics, a biopharmaceutical company, in April 2022. This prior merger showcases the potential for future success in the healthcare sector.

Listing on Nasdaq Global Market

Helix Acquisition II plans to list its shares on the Nasdaq Global Market under the ticker HLXB. This prestigious listing will provide visibility and access to a wide range of investors.

Underwriter of the Offering

Leerink Partners has been appointed as the sole underwriter for the IPO. Their expertise and extensive network will play a vital role in ensuring the success of the offering.

In conclusion, Helix Acquisition II's decision to increase the size of its IPO demonstrates confidence in its investment strategy. With a focus on the healthcare industry, affiliations with Cormorant, and a successful merger history, the company is poised for future growth and success.